Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 677 results for "glenmark pharmaceuticals"

Glenmark rises 1% after getting USFDA approval to sell Rufinamide
India Infoline

CAFC Affirms Finacea Gel Infringement Under Doctrine Of Equiva...

In Intendis GmbH v. Glenmark Pharmaceuticals Inc., USA , the Federal Circuit affirmed the district court decision that found infringement under the doctrine of equivalents. This case shows that the doctrine of equivalents still lives, that not every ... Lexology, 1 hour ago
Glenmark bags FDA approval for new generic Bio Spectrum Asia, 5 days ago

13 images for glenmark pharmaceuticals

India Infoline, 5 days ago
Business Standard India, 5 days ago, 3 weeks ago, 3 weeks ago
India Infoline, 1 week ago
Business Standard India, 1 week ago
DNA India, 5 days ago
India Infoline, 3 weeks ago
Business Standard India, 1 month ago
Financial Express, 1 month ago
India Infoline

Neutral on Glenmark Pharma with a a target at Rs 900: Motilal Oswal

Motilal Oswal maintains neutral rating on Glenmark Pharma with a 12-month target price of Rs 900. "Poor cash flow conversion, coupled with rising debt, remains a key concern for GNP," said the note. "We believe that the US business holds the key ...
 Economic Times1 week ago Underperform on Glenmark with a target at Rs 900: CLSA  Economic Times1 week ago Maintain buy on Glenmark Pharma; target Rs 1,040  Financial Express1 month ago Glenmark clarifies on FDA observations to Indore plant  India Infoline1 month ago

Glenmark Pharmaceuticals submits copy of press release

Industry: Medical/Healthcare Company Glenmark Pharmaceuticals Ltd Glenmark Pharmaceuticals has submitted a copy of Press Release dated May 19, 2016 titled Glenmark Pharmaceuticals receives ANDA approval for Rufinamide Tablets USP, 200 mg and ...
 Finalaya.com5 days ago Glenmark records a 29.89 per cent growth in Q4 FY15-16  CPhI.cn1 week ago Glenmark Q4 net jumps 13 times to Rs.143.04 crore  Prokerala1 week ago Glenmark's Consolidated Revenue for Q4 FY 2015 16 was at Rs. 23066.76 Mn recording an increase of 29.89%  FirstWord Pharma1 week ago
Business Standard India

India and US business continue to grow over 20%: Glenn Saldanha

Glenn Saldanha Glenmark Pharmaceuticals had a Rs 143 crore net profit in the March quarter, with strong revenue growth from all markets. Glenn Saldanha , chairman and managing director, talks to Aneesh Phadnis on the details. Edited excerpts: ...
 Business Standard India1 week ago India, US businesses growing over 20%: Glenn Saldanha  Smart Investor1 week ago Glenmark Q4 net profit surges 13-fold to Rs 143 cr  Business Standard1 week ago Glenmark Q4 net seen at Rs 200cr, weak LatAm biz may hurt sales  Money Control1 week ago

Glenmark gets FDA final approval to sell anti-epileptic drug in US

USFDA has granted approval for the tablets in 200 and 400 milligram dosage forms Hyderabad: Glenmark Pharmaceuticals Ltd. on Thursday said it has received final approval to sell its anti-epileptic drug in the US, after a tentative approval received ...
 Livemint.com5 days ago

Glenmark Pharmaceuticals: A lot riding on US market in fiscal 2017

Glenmark Pharmaceuticals is preparing to launch the generic version of cholesterol-lowering drug Zetia in the US, where it will be the sole generic for six months Glenmark Pharmaceuticals Ltd expects its FY17 sales to increase by 25%, with a fair ...
 Livemint.com1 week ago
Financial Express

Nestle India, Glenmark Pharma among 10 stocks in focus

The BSE Sensex and NSE Nifty opened weak on Friday after industrial production plunged to 0.1 per cent in March amidweak global cues.At 9.24 am, Sensex was trading 75.34 points down at 25,714.88, while NSE Nifty was trading 24.65 points down at ...
 MSN News US2 days ago Nestle India, Glenmark Pharma, Indian Bank among 10 stocks in focus in Friday's trade  Financial Express1 week ago Glenmark, Nestle, Polaris in focus post their Q4 nos  Money Control1 week ago Dr.Reddy's Laboratories,Glenmark Pharma results in focus  India Infoline1 week ago

Glenmark Pharma's consolidated net jumps to Rs.143 cr, dividend at 200%

Glenmark Pharmaceuticals, a Rs. 7,600 crore pharma major from Mumabi, has posted strong growth in top line and bottom line during the fourth quarter ended March 2016. Its net profit went up sharply to Rs. 143 crore from Rs. 10.61 crore as the ...
 PharmaBiz1 week ago Glenmark Pharmaceuticals reports consolidated net profit of Rs 171.48 crore in Q4  Finalaya.com1 week ago Glenmark Pharma gains on reporting consolidated net profit of Rs 171.48 crore in Q4  Finalaya.com1 week ago

Glenmark Pharmaceuticals announces change in directorate

This page uses frames, but your browser doesn't
 Capital Market1 week ago Glenmark Pharmaceuticals allots equity shares  Capital Market1 week ago
India Infoline

A tough Q4 for Dr Reddy’s,an easy one for Glenmark

Dr Reddy’s Laboratories, the third largest listed pharmaceuticals company by market capitalisation and a constituent in the Nifty 50 index, not only saw its sales take a small blow in the fourth quarter (Q4) of 2015-16 (FY16), but also saw its net profit ...
 The Financial Chronicle1 week ago See muted Q4 for Dr Reddy's, Glenmark: Prabhudas Lilladher  Money Control1 week ago Glenmark, Aurobindo, Jubilant top picks in pharma: Prabhudas  Money Control1 month ago Dr Reddys Q4 net dives 86% on Venezuelan write-off and other top pharma news  India Infoline1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - glenmark pharmaceuticals
Get updated on latest news & your favorite topics right in your inbox!
More     Less